Clinical utility of positron emission tomography with FDG for chemotherapy response monitoring: A correlative study of patients with small cell lung cancer
- German Cancer Research Center, Heidelberg (Germany); and others
This study was designed to analyze if reliable non-invasive therapy response monitoring can be obtained with positron emission tomography (PET) using F-18 labeled deoxyglucose (FDG). Furthermore, if the PET response classification at an early time point during chemotherapy, after the second or third therapy cycle, correlates with the patient survival data, which is the most reliable measure of therapy outcome. A homogeneous patient population, 39 patients with histologically confirmed SCLC, performance status {<=} 2 ECOG were studied. The study lasted from 1988-1993, with survival data of all patients known. The overall survival time was 17.1 months with a range of 3-56. Three independent response classifications techniques were compared: (a) clinical evaluation including all imaging studies except PET, (b) NSE tumor marker, and (c) PET response classification. For each technique three categories were used: (1) no change/progressive disease (NC/PD), (II) partial response (PR) and (III) complete remission (CR). The survival data in months based on the classification after the second cycle is shown in the table with the range of survival in month in parentheses.
- OSTI ID:
- 197943
- Report Number(s):
- CONF-940605-; ISSN 0161-5505; TRN: 95:007029-0083
- Journal Information:
- Journal of Nuclear Medicine, Vol. 35, Issue Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
- Country of Publication:
- United States
- Language:
- English
Similar Records
Selective Nodal Irradiation on Basis of {sup 18}FDG-PET Scans in Limited-Disease Small-Cell Lung Cancer: A Prospective Study
Clinical Outcomes of Definitive Intensity-Modulated Radiation Therapy With Fluorodeoxyglucose-Positron Emission Tomography Simulation in Patients With Locally Advanced Cervical Cancer